Cerity Partners
INDV icon

Cerity Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Cerity Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,380
Closed -$229K – 3322
2025
Q4 		$229K Buy
+6,380
New +$195K ﹤0.01% 2559

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cerity Partners's INDV Position: Q1 2026 in Review

Cerity Partners sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 6,380 shares — an estimated $229K sold.

Cerity Partners first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $229K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Cerity Partners reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cerity Partners sold 6,380 Indivior Pharmaceuticals shares in Q1 2026, an estimated $229K.
  • Cerity Partners first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cerity Partners's Indivior Pharmaceuticals position peaked at $229K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.